The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2026 | Approaching the selection between rusfertide and interferons when treating PV: advice for clinicians
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, KS, discusses the role of rusfertide in the treatment of polycythemia vera (PV) and how clinicians should approach the selection between rusfertide and interferons. Dr Yacoub notes that rusfertide will not replace standard treatments for high-risk patients, but can be used with interferon or as an alternative for low-risk patients managed with phlebotomy alone. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
